|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2000-8-22
|
|
pubmed:abstractText |
Current immunosuppressive regimens have decreased acute rejection rates during the 1st year after renal transplantation. However, this decrease has not been as marked in high-risk groups, such as African-American and Hispanic renal transplant recipients. We compared two simultaneous cohorts of altogether 36 African-American and Hispanic renal transplant recipients. Cohort one received a regimen of mycophenolate mofetil, prednisone, and a calcineurin inhibitor. The second cohort received the same protocol with the addition of Daclizumab (1 mg/kg for five doses given every 2 weeks). The median follow-up was 15.2 months (range 11.8-19.9 months). One patient in the Daclizumab-treated group and seven patients in the control group experienced an acute rejection episode. The rejection-free survival was significantly higher in the Daclizumab-treated group (94.4 %) as compared to the control group (66.7 %, Log-rank < 0.05) at 17 months after transplantation. A Cox Proportional Hazard model revealed lack of Daclizumab therapy as the only significant risk factor for acute rejection. (hazard ratio 7.0, 95 % CI = 1.1-48). The addition of the IL-2 receptor blocker Daclizumab to a triple therapy regimen may decrease early acute rejection in the high-risk groups of African-American and Hispanic patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Calcineurin,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Mycophenolic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/daclizumab,
http://linkedlifedata.com/resource/pubmed/chemical/mycophenolate mofetil
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0934-0874
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
142-5
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10836651-Adult,
pubmed-meshheading:10836651-African Continental Ancestry Group,
pubmed-meshheading:10836651-Anti-Inflammatory Agents,
pubmed-meshheading:10836651-Antibodies, Monoclonal,
pubmed-meshheading:10836651-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:10836651-Calcineurin,
pubmed-meshheading:10836651-Cohort Studies,
pubmed-meshheading:10836651-Drug Therapy, Combination,
pubmed-meshheading:10836651-Enzyme Inhibitors,
pubmed-meshheading:10836651-European Continental Ancestry Group,
pubmed-meshheading:10836651-Female,
pubmed-meshheading:10836651-Graft Rejection,
pubmed-meshheading:10836651-Humans,
pubmed-meshheading:10836651-Immunoglobulin G,
pubmed-meshheading:10836651-Immunosuppressive Agents,
pubmed-meshheading:10836651-Kidney Transplantation,
pubmed-meshheading:10836651-Male,
pubmed-meshheading:10836651-Middle Aged,
pubmed-meshheading:10836651-Mycophenolic Acid,
pubmed-meshheading:10836651-Prednisone,
pubmed-meshheading:10836651-United States
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Efficacy of Daclizumab in an African-American and Hispanic renal transplant population.
|
|
pubmed:affiliation |
Division of Renal Disease and Hypertension, University of Texas at Houston, 77030, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Controlled Clinical Trial
|
